Correlation Between Zymeworks Common and Scopus Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Zymeworks Common and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zymeworks Common and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Zymeworks Common Stock and Scopus Biopharma, you can compare the effects of market volatilities on Zymeworks Common and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zymeworks Common with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zymeworks Common and Scopus Biopharma.

Diversification Opportunities for Zymeworks Common and Scopus Biopharma

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Zymeworks and Scopus is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Zymeworks Common Stock and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Zymeworks Common is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zymeworks Common Stock are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Zymeworks Common i.e., Zymeworks Common and Scopus Biopharma go up and down completely randomly.

Pair Corralation between Zymeworks Common and Scopus Biopharma

If you would invest (100.00) in Scopus Biopharma on December 1, 2024 and sell it today you would earn a total of  100.00  from holding Scopus Biopharma or generate -100.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy0.0%
ValuesDaily Returns

Zymeworks Common Stock  vs.  Scopus Biopharma

 Performance 
       Timeline  
Zymeworks Common Stock 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Zymeworks Common Stock has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, Zymeworks Common is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.
Scopus Biopharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Scopus Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Scopus Biopharma is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Zymeworks Common and Scopus Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Zymeworks Common and Scopus Biopharma

The main advantage of trading using opposite Zymeworks Common and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zymeworks Common position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.
The idea behind Zymeworks Common Stock and Scopus Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Fundamental Analysis
View fundamental data based on most recent published financial statements
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data